NexImmune, Inc. Common Price, Forecast, Insider, Ratings, Fundamentals & Signals

Gaithersburg, md., feb. 06, 2024 (globe newswire) -- neximmune, inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under nasdaq rules.

Gaithersburg, md., feb. 02, 2024 (globe newswire) -- neximmune, inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under nasdaq rules.

Gaithersburg, md., oct. 24, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi) announces the extension of the research partnership between neximmune, yale and jdrf to explore the use of neximmune's aim nanoparticles in combination with an anti-cd3 mab to tolerize, deplete or modulate diabetes antigen-specific t cells. the extension includes an additional $300,000 grant, funded by jdrf to yale, as a part of its cures research portfolio, which includes therapies for the prevention of type 1 diabetes (t1d).

Gaithersburg, md., oct. 19, 2023 (globe newswire) -- neximmune, inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming society for immunotherapy of cancer (sitc) 38th annual meeting in san diego, ca , being held november 1-5, 2023.

Gaithersburg, md., oct. 18, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi) (the “company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced that the board of directors and stockholders of the company approved a 1-for-25 reverse stock split of the company's common stock at a special meeting of the company held on october 17, 2023. the reverse stock split will take effect after the close of trading on the nasdaq capital market at 5:00 p.m. eastern time, on wednesday, october 18, 2023. the company's common stock will open for trading under a new cusip number 65344d 208 on the nasdaq capital market on october 19, 2023, on a split-adjusted basis under the current ticker symbol "nexi...

Shares of NexImmune (NASDAQ: NEXI ) stock are skyrocketing higher ahead of the company's special meeting of stockholders. The meeting was initially set for Dec. 21 with a record date of Nov. 6.

Inexplicably, shares of embattled immunotherapy specialist NexImmune (NASDAQ: NEXI ) are skyrocketing more than 190% despite efforts to dissolve the business. An earlier attempt to vote on the liquidation and dissolution of the biotechnology enterprise failed due to a lack of quorum.

Following a dramatic spike in shares yesterday, exchange operators at Nasdaq pulled the circuit breaker on NexImmune (NASDAQ: NEXI ). Though seemingly offering innovative solutions to disease treatment, the biotechnology firm has lost almost all its value since its initial public offering in 2021.

Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back.

NexImmune (NASDAQ: NEXI ) stock is heading higher on Friday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases for filings with the Securities and Exchange Commission (SEC) that help explain why NEXI stock is up today.

Use these tips for identifying penny stocks trends in 2023 The post How to Identify Trends With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NexImmune (NASDAQ: NEXI ) stock is rocketing higher on Thursday following the release of positive preclinical trial data. According to a press release from the company, preclinical data shows AIM ACT T cells are effective in aiding BiTE therapy.

NexImmune (NASDAQ: NEXI ) stock is falling on Friday as the immunotherapies company's shares come off of a recent high earlier this week. The NEXI stock rally started earlier this week and has seen the company's shares go through several rises and falls.

GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.

NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.